SCM
MNTA

Symons Capital Management’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Symons Capital Management’s Portfolio MNTA Stock Details MNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-18,977
Closed -$321K – 90
2017
Q2 		$321K Buy
18,977
+2,895
+18% +$44.1K 0.08% 59
2017
Q1 		$215K Hold
16,082
– – 0.05% 61
2016
Q4 		$242K Buy
16,082
+1,622
+11% +$21.4K 0.06% 55
2016
Q3 		$169K Sell
14,460
-590
-4% -$6.94K 0.04% 58
2016
Q2 		$163K Buy
15,050
+835
+6% +$8.62K 0.04% 60
2016
Q1 		$132K Sell
14,215
-200
-1% -$2.15K 0.03% 59
2015
Q4 		$214K Sell
14,415
-100
-0.7% -$1.67K 0.05% 61
2015
Q3 		$238K Sell
14,515
-35
-0.2% -$716 0.06% 58
2015
Q2 		$332K Sell
14,550
-210
-1% -$4.18K 0.08% 50
2015
Q1 		$224K Sell
14,760
-1,800
-11% -$23.4K 0.05% 65
2014
Q4 		$199K Sell
16,560
-2,630
-14% -$30.1K 0.05% 71
2014
Q3 		$218K Sell
19,190
-2,460
-11% -$28.1K 0.05% 77
2014
Q2 		$262K Buy
+21,650
New +$256K 0.06% 73

Other funds holding MNTA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Symons Capital Management's MNTA Position: Q3 2017 in Review

Symons Capital Management sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q3 2017, closing a stake of 18,977 shares — an estimated $321K sold.

Symons Capital Management first reported a position in MNTA in Q2 2014 and held it in 13 quarters. The position peaked at $332K in Q2 2015. 158 funds tracked by Wall St. Rank hold MNTA as of Q3 2017.

  • Symons Capital Management reported no remaining Momenta Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • Symons Capital Management sold 18,977 Momenta Pharmaceuticals, Inc. shares in Q3 2017, an estimated $321K.
  • Symons Capital Management first reported a position in Momenta Pharmaceuticals, Inc. in Q2 2014 and held it in 13 quarters.
  • Symons Capital Management's Momenta Pharmaceuticals, Inc. position peaked at $332K in Q2 2015.
  • 158 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q3 2017.

Based on Symons Capital Management's 13F filing for Q3 2017, filed 3 Nov 2017.